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Objectives:  Ramucirumab  plus  docetaxel  prolongs  survival  in  patients  with  non-small  cell  lung cancer
(NSCLC)  with  disease  progression  after  platinum-based  therapy.  This  phase  II, double-blind,  randomized,
placebo-controlled  study  assessed  efﬁcacy  and  safety  of  second-line  ramucirumab-docetaxel  in  Japanese
patients  with  NSCLC.
Materials and methods:  Patients  with  NSCLC  with  progression  after  platinum-based  therapy  (28  Japanese
sites;  19 December,  2012 to  22  May,  2015)  were  randomized  (computer-generated  sequence)  to ramu-
cirumab  10  mg/kg  or placebo,  followed  by docetaxel  60 mg/m2 (Day  1, 21-day  cycle).  Prior  epidermal
growth  factor  receptor  (EGFR)  tyrosine  kinase  inhibitor  (TKI)  monotherapy  was  prohibited  in  the primary
population,  but  EGFR  mutation-positive  NSCLC  patients  who  were  treated  with  EGFR-TKI  were  enrolledandomized phase II trial as a separate  exploratory  population.  Primary  endpoint  was  progression-free  survival  (PFS);  secondary
outcomes  included  overall  survival,  tumor  response  rates,  and  safety.  Investigator  tumor  assessments
were  used  for  the  efﬁcacy  endpoints.
Results:  In  the  primary  population  (N  = 160  randomized,  n = 157  treated),  median  (95% CI)  PFS
was longer  with  ramucirumab-docetaxel  (5.22  [3.52–6.97]  months;  n  =  76)  than  with  placebo-
docetaxel (4.21  [2.83–5.62]  months;  n  = 81);  hazard  ratio  0.83  (95%  CI  0.59–1.16).  Median  (95%
CI) overall  survival  was  15.15  (12.45–26.55)  months  with  ramucirumab-docetaxel  and  14.65
Abbreviations: AE, adverse event; CI, conﬁdence interval; CR, complete response; CT, computed tomography; DCR, disease control rate; ECOG, Eastern Cooperative
ncology Group; EGFR, epidermal growth factor receptor; FAS, full analysis set; HR, hazard ratio; ILD, interstitial lung disease; IRRC, Independent Response Review Committee;
edDRA, medical dictionary for regulatory activities; MRI, magnetic resonance imaging; NCI-CTCAE, national cancer institute-common terminology criteria for adverse
vents; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response;
S,  performance status; RECIST, response evaluation criteria in solid tumors; SD, stable disease; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.
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ttp://dx.doi.org/10.1016/j.lungcan.2016.07.019
169-5002/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
c-nd/4.0/).
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con  (11.93–24.44)  months  with  placebo-docetaxel  (hazard  ratio  [95%  CI]  0.86  [0.56–1.32]).  Objective
response  rate  (28.9%  vs  18.5%)  and  disease  control  rate  (78.9%  vs  70.4%)  were  numerically  greater  with
ramucirumab-docetaxel  than  with  placebo-docetaxel.  Incidence  and  severity  of  most  adverse  events
were  similar,  but febrile  neutropenia  was  more  common  with  ramucirumab-docetaxel  (34.2%)  than  with
placebo-docetaxel  (19.8%).
Conclusion:  Second-line  ramucirumab-docetaxel  improved  PFS  similar  to that  seen in  the  REVEL  trial  with
a  manageable  safety  proﬁle  in Japanese  patients  with  NSCLC.
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. Introduction
The vascular endothelial growth factor (VEGF) pathway is a
rucial target for cancer treatment [1]. Ramucirumab is a fully
uman immunoglobulin G1 monoclonal antibody that binds with
igh afﬁnity to VEGF receptor-2, preventing VEGF binding and
ctivation [2]. Randomized, placebo-controlled, phase III studies
ave shown that second-line ramucirumab (with or without pacli-
axel) signiﬁcantly improves survival in patients with advanced
astric/gastro-esophageal [3,4] or colorectal [5] cancer. The ran-
omized, phase III REVEL trial demonstrated that ramucirumab
dded to docetaxel prolongs overall survival (OS) in patients with
tage IV non-small cell lung cancer (NSCLC) who progressed after
latinum-based therapy [6]. Median OS was 10.5 months with
amucirumab-docetaxel and 9.1 months with placebo-docetaxel
hazard ratio [HR] 0.86, 95% conﬁdence interval [CI] 0.75–0.98;
 = 0.023) [7].
Epidermal growth factor receptor (EGFR) tyrosine kinase
nhibitors (TKIs) are recommended as ﬁrst-line monotherapy for
atients with NSCLC who have an activating EGFR mutation [8].
n Japan, 26% to 49% of patients with NSCLC are EGFR mutation-
ositive, higher than in non-East Asians [9,10]. In most Japanese
atients with EGFR mutation, geﬁtinib or erlotinib is used as ﬁrst-
ine or second-line monotherapy [8,11,12]. However, second-line
reatment options for Japanese patients with wild-type EGFR are
imited.
Docetaxel is approved for patients with NSCLC who progress
fter 1 prior regimen, based on phase III trials [13,14]. Unlike EGFR-
KIs [15] and pemetrexed, which preferentially beneﬁts patients
ith non-squamous NSCLC [16], docetaxel is expected to have
fﬁcacy independent of EGFR status and histology. In Japan, the
pproved docetaxel dose for NSCLC is 60 mg/m2 [17,18]. In the
EVEL trial, the incidence of neutropenia and febrile neutropenia
as increased in the East Asian subgroup who received the planned
ocetaxel dose of 75 mg/m2 [7]. After a mid-trial amendment, 24
ewly enrolled East Asian patients (27% of randomized East Asian
atients) received a lower docetaxel dose of 60 mg/m2 [7]. Because
f the limited number of East Asian patients treated at this lower
ose, the efﬁcacy and safety of 60 mg/m2 docetaxel combined with
amucirumab in East Asian patients need to be conﬁrmed.
This phase II, randomized, placebo-controlled study evalu-
ted the efﬁcacy and safety of ramucirumab in combination with
ocetaxel 60 mg/m2 in Japanese patients with stage IV NSCLC
hose disease has progressed during or after 1 platinum-based
hemotherapy regimen. Patients who received previous EGFR-TKI
onotherapy in addition to platinum-based chemotherapy could
articipate as a separate, exploratory population.
. Materials and methods.1. Study design
This randomized, placebo-controlled, double-blind, multicen-
er, phase II study was conducted at 28 Japanese study sitesblished  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
between 19 December, 2012 (ﬁrst patient enrolled) and 18
December, 2014 (cutoff for progression-free survival [PFS] anal-
ysis), then updated 22 May, 2015 for OS analysis. The study was
approved by the institutional review boards of all sites, conducted
in accordance with the principles of the Declaration of Helsinki
and Good Clinical Practice, and registered at ClinicalTrials.gov
(NCT01703091). All patients provided written informed consent
before any study-related procedures.
2.2. Study population
The primary population included patients with NSCLC whose
disease had progressed during or after 1 ﬁrst-line, platinum-
based therapy (with or without maintenance therapy) without
prior EGFR-TKI monotherapy. The exploratory population included
patients with EGFR mutation-positive NSCLC whose disease had
progressed during or after 1 platinum-based therapy (with or
without maintenance therapy) and whose prior therapy included
EGFR-TKI monotherapy.
Male and female patients aged ≥20 years who met  the follow-
ing criteria were eligible: histologically or cytologically conﬁrmed
stage IV NSCLC (squamous or non-squamous); disease progression
during or after 1 ﬁrst-line, platinum-based therapy with or without
maintenance therapy; measurable disease documented by com-
puted tomography (CT) or magnetic resonance imaging (MRI) as
deﬁned by Response Evaluation Criteria in Solid Tumors (RECIST),
Version 1.1; Eastern Cooperative Oncology Group (ECOG) perfor-
mance status (PS) 0 or 1; adequate organ function; and resolution
of all clinically signiﬁcant toxic effects of prior anticancer ther-
apy to Grade ≤1 (National Cancer Institute-Common Terminology
Criteria for Adverse Events [NCI-CTCAE], Version 4.0). Previous
bevacizumab treatment was allowed. Patients were excluded if
they had untreated central nervous system metastases (treated
asymptomatic brain metastases eligible); major blood vessel inva-
sion or signiﬁcant intratumor cavitation; pre-existing interstitial
lung disease (ILD); signiﬁcant bleeding disorders, vasculitis, or
Grade 3–4 gastrointestinal bleeding within 3 months; arterial
thromboembolic event or gastrointestinal perforation and/or ﬁs-
tula within 6 months; gross hemoptysis within 2 months; prior
therapy with ramucirumab and/or docetaxel; or concurrent treat-
ment with any other anticancer therapy.
2.3. Treatment protocol
Patients were randomized (1:1), using a computer-generated
random sequence accessed by an interactive voice response system,
to receive intravenous ramucirumab (Cyramza®, Eli Lilly and Com-
pany, Indianapolis, IN, USA) 10 mg/kg or placebo (60-min infusion),
followed by intravenous docetaxel 60 mg/m2 (60-min infusion)
on Day 1 of every 21-day cycle until progressive disease (PD) or
unacceptable toxicity (Fig. 1). Randomization of the primary pop-
ulation was stratiﬁed by ECOG PS (0/1), sex (female/male), and
prior maintenance therapy (yes/no). The exploratory population
was randomized, but not stratiﬁed. To preserve blinding, ramu-
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Fig. 1. Study design. Abbreviations: DOC = docetaxel; EGFR-TKI = epidermal g
irumab and placebo preparations appeared identical. The start of
 treatment cycle could be delayed up to 2 weeks for recovery of
rotocol-speciﬁed events. If a delay >2 weeks due to unresolved
oxicity was necessary, one or both drugs (depending on causality)
ere discontinued. The other agent could be continued, with the
atient remaining on study, if clinically indicated. Supportive care
or disease-related symptoms and treatment-associated toxicity
as offered to all patients.
Following discontinuation, all patients were followed for sur-
ival and information on subsequent systemic anticancer therapy
as collected. For patients without PD during treatment, informa-
ion on disease progression was collected at least every 3 months
r until study completion.
.4. Outcomes
The primary outcome was PFS in the primary population,
eﬁned as the time from randomization until PD or death. Sec-
ndary efﬁcacy outcomes in the primary population included OS
time from randomization to death from any cause; follow-up
eriod was 1 year after the last enrolled patient started study treat-
ent); objective response rate (ORR; proportion of randomized
atients with best overall response of complete response [CR] or
artial response [PR]); and disease control rate (DCR; proportion of
andomized patients with best overall response of CR, PR, or sta-
le disease [SD]). Outcomes in the exploratory population included
FS, OS, ORR, and DCR. Investigator tumor assessments were used
or the efﬁcacy endpoints.
A baseline CT scan or MRI  of chest and upper abdomen and a con-
rast CT scan or MRI  of the brain were required. Tumor assessments
ere performed every 6 weeks (±3 days) after the ﬁrst dose of study
herapy until radiographic PD were determined. An Independent
esponse Review Committee (IRRC) reviewed CT scans and MRI
ata for tumor assessments.
Adverse events (AEs) were collected at every visit, coded to
edical Dictionary for Regulatory Activities (MedDRA, Version
7.1) terms, and graded using NCI-CTCAE criteria. Laboratory tests
blood chemistry, hematology, and urinalysis), vital signs, concomi-
ant therapies, electrocardiograms, echocardiogram/multiple-
ated acquisition, pregnancy tests, and physical examinations were
onducted at regular intervals.
In the primary population, blood samples for determination of
erum ramucirumab concentrations were collected before infusion
trough) for Doses 1–6 and 1 h after infusion for Doses 1, 2, and 4,
ith additional samples collected at Doses 1 and 2 and at follow-up.
lood samples for determination of plasma docetaxel concentra-
ions were collected over the ﬁrst 2 cycles and before Cycle 3. factor receptor tyrosine kinase inhibitor; PL = placebo; RAM = ramucirumab.
Ramucirumab and docetaxel concentrations were measured using
validated assays.
2.5. Statistical analysis
A sample size of 154 (134 events) was  calculated to provide a
90% probability of obtaining an estimated HR <1 (77% probability
of estimated HR <0.9) for the primary outcome, PFS in the pri-
mary population, assuming a true HR of 0.8 (median PFS, 3.75 vs 3
months). For the exploratory population, the sample size was  set at
40 based on an 81% probability of obtaining the better estimate in
the ramucirumab-docetaxel arm, assuming true ORRs of 20% and
10% in the ramucirumab-docetaxel and placebo-docetaxel arms,
respectively.
The full analysis set (FAS), comprised all randomized and treated
patients whose prior therapy did not include EGFR-TKI monother-
apy, and the exploratory analysis set comprised all randomized
patients whose prior therapy included EGFR-TKI monotherapy.
For the FAS, the primary endpoint of PFS was  analyzed using the
Kaplan-Meier method, and HRs and 95% CIs for treatment effect
were estimated using a stratiﬁed Cox proportional hazards model
(stratiﬁcation factors used for randomization). Predeﬁned sensitiv-
ity analyses were performed to test the effect of different censoring
rules on PFS results (Supplementary Table 1). Predeﬁned subgroup
analyses were performed based on ECOG PS, sex, prior maintenance
therapy, smoking history, histology, best response to platinum-
based chemotherapy, prior taxane treatment, prior bevacizumab
treatment, EGFR status, age, and time since prior therapy. Over-
all survival was analyzed using the same method as PFS. Tumor
response rates (ORR and DCR) are reported with 95% CIs. The
same methods were used to analyze PFS, OS, ORR, and DCR in the
exploratory population.
Statistical tests were performed, but P values are shown for ref-
erence only. Tests of treatment effects were conducted at a 2-sided
alpha level of 0.05, tests of interactions were conducted at a 2-
sided alpha level of 0.10, and CIs are given at a 2-sided 95% level,
unless otherwise stated. Statistical analyses were performed using
SAS software (SAS, Version 9.2) and Sigma PlotTM (San Jose, CA,
USA).
3. Results
3.1. Patient characteristicsThe primary population included 160 patients (79
ramucirumab-docetaxel, 81 placebo-docetaxel); 3 patients in
the ramucirumab-docetaxel arm were not treated because
of subject (n = 2) or investigator (n = 1) decision (Fig. 2). The
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Entered (N=228)
Enrolled
N=197
Primary Population
(No prior EGFR-TKI)
(N=160)
Not treated
(n=3)
Full Analysis Set
(FAS)
N=157
Discontinued (n=70)
Progressive disease (n=36)
Adverse event (n=28)
Subject decision (n=3)
Discontinued (n=76)
Progressive disease (n=57)
Adverse event (n=14)
Subject decision (n=4)
Discontinued (n=16)
Progressive disease (n=6)
Adverse event (n=10)
Discontinued (n=17)
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Adverse event (n=6)
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Not treated
(n=1)
Not treated
(n=1)
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(Prior EGFR-TKI)
(N=37)
Not enrolled (n=31)
RAM+DOC
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Fig. 2. Patient disposition. Abbreviations: DOC = docetaxel; EGFR-TKI = epiderma
emaining 157 patients comprised the FAS. The exploratory
opulation included 37 patients (19 ramucirumab-docetaxel,
8 placebo-docetaxel); 1 patient in each arm was not treated
ecause of subject (ramucirumab-docetaxel) or investigator
placebo-docetaxel) decision (Fig. 2).
At the time of PFS analysis, 11 patients in the primary population
6 ramucirumab-docetaxel, 5 placebo-docetaxel) and 2 patients in
he exploratory population (both ramucirumab-docetaxel) were
till on treatment (Fig. 2). The most common reasons for discon-
inuation in both arms were PD and AEs (Fig. 2).
Demographic and baseline clinical characteristics were similar
n the 2 arms in the FAS (Table 1) and reﬂected the overall popula-
ion of Japanese patients with NSCLC [19].
.2. Progression-free survival
Progression-free survival was approximately 1 month longer
ith ramucirumab-docetaxel (median [95% CI]: 5.22 [3.52–6.97]
onths) than with placebo-docetaxel (4.21 [2.83–5.62] months;
tratiﬁed HR 0.83 [0.59–1.16]) (Fig. 3). The robustness of the PFS
nalysis is supported by prespeciﬁed sensitivity analyses, which
enerated consistent HRs (Supplementary Table 1), and by inde-
endent tumor assessments by the IRRC (median [95% CI] PFS: 5.75
4.30–7.29] months with ramucirumab-docetaxel; 4.07 [2.83–5.62]
onths with placebo-docetaxel; stratiﬁed HR 0.70 [0.50–1.00]).
.3. Overall survival
At the time of OS analysis, median (95% CI) OS was  15.15
12.45–26.55) months with ramucirumab-docetaxel and 14.65
11.93–24.44) months with placebo-docetaxel (stratiﬁed HR [95%
I] 0.86 [0.56–1.32]) (Fig. 4). Similar proportions of patients
eceived further systemic therapies after study discontinuation
n both arms (ramucirumab-docetaxel, 67.1%; placebo-docetaxel,
4.1%).
PL+DOC 81 77 63 55 46 24 17 9 6 1 0
Fig. 4. Overall survival (full analysis set). Abbreviations: CI = conﬁdence interval;
DOC = docetaxel; HR = hazard ratio; PL = placebo; RAM = ramucirumab.
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Table 1
Baseline characteristics.
Parameter Ramucirumab-docetaxel (N = 76) Placebo-docetaxel (N = 81)
Age, median (min, max), years 65.6 (29, 78) 64.9 (27, 79)
<65  years, n (%) 36 (47.4) 42 (51.9)
≥65  years, n (%) 40 (52.6) 39 (48.1)
Sex,  n (%)
Male 59 (77.6) 62 (76.5)
Female 17 (22.4) 19 (23.5)
ECOG  PS, n (%)
0 34 (44.7) 32 (39.5)
1  42 (55.3) 49 (60.5)
Smoking history, n (%)
Ever 62 (81.6) 67 (82.7)
Never  14 (18.4) 14 (17.3)
Histology, n (%)
Non-squamous 67 (88.2) 72 (88.9)
Squamous 9 (11.8) 9 (11.1)
EGFR status, n (%)
Wild-type 70 (92.1) 77 (95.1)
Unknown 6 (7.9) 4 (4.9)
Prior taxane, n (%)
Yes 24 (31.6) 23 (28.4)
No  52 (68.4) 58 (71.6)
Prior  bevacizumab, n (%)
Yes 23 (30.3) 24 (29.6)
No  53 (69.7) 57 (70.4)
Best  response to platinum, n (%)
CR/PR/SD 69 (90.8) 70 (86.4)
PD  4 (5.3) 9 (11.1)
Not  applicable 3 (3.9) 2 (2.5)
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abbreviations: CR, complete response; ECOG PS, Eastern Cooperative Oncology Gr
inimum; PD, progressive disease; PR, partial response; SD, stable disease.
.4. Tumor response
Both ORR and DCR were numerically greater with ramucirumab-
ocetaxel than with placebo-docetaxel (ORR [95% CI]: 28.9%
19.1%–40.5%] vs 18.5% [10.8%–28.7%]; DCR [95% CI]: 78.9%
68.1%–87.5%] vs 70.4% [59.2%–80.0%]). Independent IRRC evalu-
tion yielded similar results (ORR [95% CI]: 26.3% [16.9%–37.7%] vs
9.8% [11.7%–30.1%]; DCR [95% CI]: 78.9% [68.1%–87.5%] vs 66.7%
55.3%–76.8%]). There were no complete responses in either arm.
n the ramucirumab-docetaxel arm, best responses of PR, SD, and
D were reported in 22 (28.9%), 38 (50.0%), and 13 (17.1%) patients,
espectively (2 patients not done, 1 patient not evaluable). In the
lacebo-docetaxel arm, best responses of PR, SD, and PD were
eported in 15 (18.5%), 42 (51.9%), and 23 (28.4%) patients, respec-
ively (1 patient not done).
.5. Exploratory population
In the exploratory population of EGFR mutation-positive
atients with prior EGFR-TKI treatment, median PFS (5.65 vs
.37 months), ORR (44.4% vs 41.2%), and DCR (88.9% vs 76.5%)
ere numerically greater with ramucirumab-docetaxel than with
lacebo-docetaxel. At the time of OS analysis, median (95% CI) OS
as 17.28 (7.06- not available) months in the placebo-docetaxel
rm, but could not be determined in the ramucirumab-docetaxel
rm due to insufﬁcient events (6 deaths among 18 patients).
he probability (95% CI) that OS was at least 12 months was
8.9% (62.4%–97.1%) in the ramucirumab-docetaxel arm and 58.8%
32.5%–77.8%) in the placebo-docetaxel arm.
.6. Safety.6.1. Extent of exposure
Median duration of ramucirumab or placebo therapy was 13.0
eeks in the ramucirumab-docetaxel arm (median 4 infusions)
nd 12.6 weeks in the placebo-docetaxel arm (median 4 infusions).rformance status; EGFR, epidermal growth factor receptor; max, maximum; min,
Mean relative dose intensities of ramucirumab, placebo, and doc-
etaxel exceeded 90% (range, 90.0%–93.1%) in both arms.
3.6.2. Adverse events
All patients in the FAS reported at least 1 AE, and most patients
reported at least 1 Grade ≥3 AE (Table 2). The most commonly
reported AEs were hematological, particularly neutropenia and
leukopenia, reported by ≥89.5% of patients in both arms. The most
common non-hematological AEs (reported by ≥50% of patients in
either arm) included alopecia, decreased appetite, and stomatitis.
Grade ≥3 hematological AEs occurring in ≥10% of patients in the
ramucirumab-docetaxel arm included neutropenia, leukopenia,
and febrile neutropenia (Table 2). For neutropenia, the incidences
by grade were similar in the ramucirumab-docetaxel and placebo-
docetaxel arms (Grade 3: 27.6% vs 28.4%; Grade 4: 61.8% vs 61.7%).
The incidence of febrile neutropenia of any grade was higher
with ramucirumab-docetaxel (34.2%) than with placebo-docetaxel
(19.8%), as was the use of granulocyte-colony stimulating factor
(43.6% vs 36.7%).
More patients in the ramucirumab-docetaxel arm had bleeding
or hemorrhage events than in the placebo-docetaxel arm (Table 2).
However, the incidence of Grade ≥3 bleeding events was very
low in both arms; transfusion was performed in only 2 patients
in the ramucirumab-docetaxel arm and 1 patient in the placebo-
docetaxel arm. The incidences of proteinuria and hypertension
were higher with ramucirumab-docetaxel than with placebo-
docetaxel. The incidences of other AEs of special interest were low
and similar in both arms.
The proportion of patients with a serious AE was  similar in
the ramucirumab-docetaxel and placebo-docetaxel arms (28.9% vs
33.3%). The most frequently reported serious AE was  febrile neu-
tropenia (10.5% ramucirumab-docetaxel, 6.2% placebo-docetaxel).
During the study, 40 patients treated with ramucirumab-docetaxel
and 46 patients treated with placebo-docetaxel died; 1 death in
each arm was  due to an AE (acute respiratory failure and lymphan-
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Table  2
Adverse events occurring in at least 10% of patients in the ramucirumab-docetaxel arm or of special interest.
Adverse event, n (%) Ramucirumab-docetaxel (N = 76) Placebo-docetaxel (N = 81)
Any grade Grade ≥3 Any grade Grade ≥3
Any 76 (100.0) 71 (94.7) 81 (100.0) 77 (95.1)
Hematological adverse events
Neutropeniaa 72 (94.7) 68 (89.5) 80 (98.8) 73 (90.1)
Leukopeniaa 68 (89.5) 53 (69.7) 74 (91.4) 58 (71.6)
Anemiaa 30 (39.5) 2 (2.6) 37 (45.7) 3 (3.7)
Febrile  neutropenia 26 (34.2) 26 (34.2) 16 (19.8) 16 (19.8)
Thrombocytopeniaa 19 (25.0) 3 (3.9) 3 (3.9) 3 (3.7)
Non-hematological adverse events
Alopecia 51 (67.1) 0 50 (61.7) 0
Decreased appetite 49 (64.5) 8 (10.5) 44 (54.3) 5 (6.2)
Stomatitis 38 (50.0) 4 (5.3) 23 (28.4) 0
Malaise 37 (48.7) 0 39 (48.1) 0
Nausea 27 (35.5) 0 33 (40.7) 1 (1.2)
Pyrexia 25 (32.9) 0 24 (29.6) 0
Fatiguea 24 (31.6) 1 (1.3) 21 (25.9) 0
Hypoalbuminemiaa 24 (31.6) 2 (2.6) 16 (19.8) 1 (1.2)
Peripheral edema 24 (31.6) 1 (1.3) 20 (24.7) 0
Diarrhea 22 (28.9) 2 (2.6) 18 (22.2) 1 (1.2)
Dysgeusia 19 (25.0) 0 19 (23.5) 0
AST  increased 18 (23.7) 1 (1.3) 7 (8.6) 1 (1.2)
Nail  discoloration 17 (22.4) 0 15 (18.5) 0
Dry  skin 15 (19.7) 0 13 (16.0) 0
Insomnia 15 (19.7) 0 14 (17.3) 0
ALT  increased 14 (18.4) 0 3 (3.7) 1 (1.2)
Neuropathya 13 (17.1) 0 24 (29.6) 0
Myalgia 13 (17.1) 0 15 (18.5) 0
Arthralgia 12 (15.8) 0 12 (14.8) 0
Constipation 11 (14.5) 1 (1.3) 23 (28.4) 0
Pleural effusion 10 (13.2) 1 (1.3) 3 (3.7) 0
Vomiting 9 (11.8) 0 22 (27.2) 0
Hiccups 8 (10.5) 0 6 (7.4) 0
Face  edema 8 (10.5) 0 3 (3.7) 0
Palmar-plantar erythrodysesthesia syndrome 8 (10.5) 1 (1.3) 2 (2.5) 0
Adverse events of special interest
Bleeding or hemorrhage 39 (51.3) 2 (2.6) 23 (28.4) 0
Epistaxis 36 (47.4) 0 14 (17.3) 0
Pulmonary hemorrhage eventsb 8 (10.5) 1 (1.3) 6 (7.4) 0
Proteinuria 20 (26.3) 3 (3.9) 8 (9.9) 0
Hypertension 6 (7.9) 4 (5.3) 0 0
Infusion-related reaction 3 (3.9) 0 5 (6.2) 0
Renal  failure 2 (2.6) 1 (1.3) 2 (2.5) 0
Venous thromboembolic event 1 (1.3) 0 2 (2.5) 1 (1.2)
Fistula  1 (1.3) 0 0 0
Arterial thromboembolic event 0 0 1 (1.2) 1 (1.2)
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[bbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase.
a Consolidated term, MedDRA (version 17.1).
b Including hemoptysis and pulmonary hemorrhage.
iosis carcinomatosa in the ramucirumab-docetaxel arm; septic
hock in the placebo-docetaxel arm).
The number of patients with ILD was  similar in the
amucirumab-docetaxel (8 [10.5%]; 1 [1.3%] Grade 3, 1 [1.3%] Grade
) and placebo-docetaxel (6 [7.4%]; 3 [3.7%] Grade 3) arms. The
tudy’s ILD Monitoring Committee reported that diffuse alveolar
amage patterns were observed in 2 of 8 ILD-related events in the
amucirumab-docetaxel arm, which were resolving at the time of
nalysis. No diffuse alveolar damage patterns were observed in the
lacebo-docetaxel arm.
.7. Pharmacokinetic analyses
Ramucirumab concentrations 1 h after infusion were relatively
onstant between Doses 1 and 4, and trough concentrations stabi-
ized by Dose 5 (Supplementary Fig. 1). Docetaxel pharmacokinetics
ere not affected by ramucirumab coadministration (Supplemen-
ary Fig. 2). These results are consistent with the REVEL trial
unpublished data) and a ramucirumab-docetaxel interaction study
20].4. Discussion
The REVEL trial demonstrated that ramucirumab improves sur-
vival when combined with docetaxel in patients with NSCLC with
disease progression after platinum-based chemotherapy [7]. How-
ever, because few East Asian patients were enrolled in REVEL,
particularly those treated with the lower docetaxel dose of
60 mg/m2, we  sought to evaluate the efﬁcacy and safety of this
combination in Japanese patients.
In this study, the addition of ramucirumab to docetaxel resulted
in an improvement in median PFS of approximately 1 month, sug-
gesting greater clinical activity over docetaxel alone (HR 0.83).
Our results were consistent with those of REVEL, which showed
a PFS increase of 1.5 months (HR 0.76) and an OS increase of 1.4
months (HR 0.86) [7]. A favorable effect of ramucirumab-docetaxel
was also evident in the ORR and DCR. Post study further systemic
therapies were similar in both arms and immune check-points
inhibitors were hardly available after study discontinuation in this
study. These results suggest that ramucirumab in combination
with docetaxel may  provide clinical beneﬁt as second-line ther-
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py in Japanese patients with NSCLC, consistent with the REVEL
rial results. Similar effects on PFS, ORR, and DCR (and possibly OS)
ere also seen in the exploratory population of EGFR mutation-
ositive patients with prior EGFR-TKI therapy, suggesting that
amucirumab-docetaxel may  also provide clinical beneﬁt in these
atients.
The observed safety proﬁle was consistent with that estab-
ished in pivotal studies of ramucirumab [3–5,7,21] and doc-
taxel [7,13,14,22]. Ramucirumab in combination with docetaxel
0 mg/m2 was generally well tolerated, with manageable AEs. The
ncidence and severity of most hematological AEs were similar
n the 2 arms, although febrile neutropenia was more common
ith ramucirumab-docetaxel (34.2%) than with placebo-docetaxel
19.8%). Indeed, febrile neutropenia was more common in both
rms than in the overall REVEL population (16% and 10% with
amucirumab-docetaxel and placebo-docetaxel, respectively) [7],
nd in a phase 3 study of Japanese patients treated with second-
ine docetaxel at 60 mg/m2 (7.1%) [19]. However, although all cases
f febrile neutropenia in the current study were Grade 3, only 1
ase resulted in discontinuation (placebo-docetaxel arm), suggest-
ng that febrile neutropenia can be effectively managed.
Limitations of the study include its phase II nature and limited
ample size, restricting our ability to conﬁrm any potential bene-
ts of ramucirumab-docetaxel. However, because our results are
imilar to the REVEL trial, we believe ramucirumab-docetaxel may
rovide clinical beneﬁt in Japanese patients with NSCLC, including
hose with squamous or non-squamous histologies and those with
ild-type EGFR.
In this study, the addition of ramucirumab to docetaxel pro-
onged PFS in Japanese patients with NSCLC who had previously
eceived platinum-based chemotherapy. Favorable treatment
ffects of ramucirumab added to docetaxel were observed for
S and tumor response rates, and the combination therapy
ad a manageable safety proﬁle. Exploratory analyses suggested
hat ramucirumab-docetaxel may  also provide clinical beneﬁt in
GFR mutation-positive patients with prior EGFR-TKI therapy.
ogether with the REVEL trial results, our ﬁndings suggest that
amucirumab-docetaxel may  be a promising therapeutic option
or patients with advanced NSCLC who have progressed after
latinum-based chemotherapy.
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